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Abstract
Background: The leishmaniases are a complex of neglected tropical diseases caused by more than 20 Leishmania parasite
species, for which available therapeutic arsenal is scarce and unsatisfactory. Pentavalent antimonials (SbV) are currently the
first-line pharmacologic therapy for leishmaniasis worldwide, but resistance to these compounds is increasingly reported.
Alkyl-lysophospoholipid analogs (ALPs) constitute a family of compounds with antileishmanial activity, and one of its
members, miltefosine, has been approved as the first oral treatment for visceral and cutaneous leishmaniasis. However, its
clinical use can be challenged by less impressive efficiency in patients infected with some Leishmania species, including L.
braziliensis and L. mexicana, and by proneness to develop drug resistance in vitro.
Methodology/Principal Findings: We found that ALPs ranked edelfosine.perifosine.miltefosine.erucylphosphocholine
for their antileishmanial activity and capacity to promote apoptosis-like parasitic cell death in promastigote and amastigote
forms of distinct Leishmania spp., as assessed by proliferation and flow cytometry assays. Effective antileishmanial ALP
concentrations were dependent on both the parasite species and their development stage. Edelfosine accumulated in and
killed intracellular Leishmania parasites within macrophages. In vivo antileishmanial activity was demonstrated following
oral treatment with edelfosine of mice and hamsters infected with L. major, L. panamensis or L. braziliensis, without any
significant side-effect. Edelfosine also killed SbV-resistant Leishmania parasites in in vitro and in vivo assays, and required
longer incubation times than miltefosine to generate drug resistance.
Conclusions/Significance: Our data reveal that edelfosine is the most potent ALP in killing different Leishmania spp., and it
is less prone to lead to drug resistance development than miltefosine. Edelfosine is effective in killing Leishmania in culture
and within macrophages, as well as in animal models infected with different Leishmania spp. and SbV-resistant parasites.
Our results indicate that edelfosine is a promising orally administered antileishmanial drug for clinical evaluation.
Citation: Varela-M RE, Villa-Pulgarin JA, Yepes E, Mu¨ller I, Modolell M, et al. (2012) In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and
SbV-Resistant Parasites. PLoS Negl Trop Dis 6(4): e1612. doi:10.1371/journal.pntd.0001612
Editor: Jayne Raper, New York University School of Medicine, United States of America
Received November 7, 2011; Accepted February 27, 2012; Published April 10, 2012
Copyright:  2012 Varela-M et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Spanish Ministerio de Ciencia e Innovacio´n (SAF2008-02251; SAF2011-30518; RD06/0020/1037 from Red Tema´tica de
Investigacio´n Cooperativa en Ca´ncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union; and TRA2009-
0275), European Community’s Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986), Junta de Castilla y Leo´n (CSI052A11-2; GR15-
Experimental Therapeutics and Translational Oncology Program) and Spain-UK International Joint Project grant from The Royal Society-CSIC (2004GB0032). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: FM is co-founder of Apointech and a member of its scientific advisory board. REV, JAVP and EY are employees of Apointech. The other
authors disclose no potential conflicts of interest.
* E-mail: fmollin@usal.es
. These authors contributed equally to this work.
Introduction
The impact of the leishmaniases on human health has been
grossly underestimated for many years, and this complex of
diseases has been classified by the World Health Organization
(WHO) as one of the most neglected tropical diseases [1]. During
the last decade, endemic areas have been spreading and a sharp
increase in the number of leishmaniasis cases has been recorded.
The WHO classifies leishmaniasis as a category 1 disease
(‘‘emerging and uncontrolled’’), and there is an urgent need to
develop new therapeutic drugs and approaches. Currently, about
350 million people in 98 countries around the world are at risk,
and an estimated 12 million people are infected [1]. Despite
progress in the diagnosis and treatment, leishmaniasis remains a
major public health problem, particularly in tropical and sub-
tropical developing countries. Published figures indicate an
estimated incidence of two million new cases per year, with 1.5
million cases of self-healing, but disfiguring, cutaneous leishman-
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iasis, and 500,000 cases of life-threatening visceral leishmaniasis
[1,2]. Approximately 60,000 people die from visceral leishmaniasis
each year, a rate surpassed among parasitic diseases only by
malaria; and a loss of about 2.4 million disability-adjusted life
years (DALYs) throughout the world has been calculated as the
total disease burden of leishmaniasis [1–3]. Furthermore, a
number of reports have emphasized the increasing importance
of visceral leishmaniasis as an opportunistic infection among HIV-
positive patients in areas where both infections are endemic [4].
The chemotherapy currently available for the leishmaniases is
far from satisfactory and presents several problems, including
toxicity, many adverse side-effects, high costs and development
of drug resistance [2,5]. Two pentavalent antimonial (SbV)
compounds, sodium stibogluconate (Pentostam) and meglumine
antimoniate (Glucantime), were first introduced in the 1940’s
and have since been used as first-line chemotherapeutic agents
against all forms of leishmaniasis through parenteral adminis-
tration. Although SbV, administered by intramuscular or
intravenous route, remains the first-line drug for the treatment
of leishmaniasis worldwide, its efficacy is becoming increasingly
lower [6], and highly depends on Leishmania species and distinct
endemic regional variations, even within the same country.
Resistance is now common in India, and rates of resistance have
been shown to be higher than 60% in parts of the state of Bihar,
in north-east India [7,8]. In addition, the incidence of adverse
effects, including myalgia, arthralgias, pancreatitis, nephrotoxi-
city, hepatotoxicity, and cardiotoxicity [1,2,9], makes the search
for new alternative medicines to SbV an urgent issue, and a
number of drugs are now in clinical trials [10]. Intravenous
infusion of liposomal amphotericin B (AmBisome) is at present
the most effective anti-Leishmania drug [2,11], but its relatively
high cost makes it unaffordable in several poor areas of the world
where the disease is more prevalent [2]. In addition, the
requirement for long periods of parenteral administration,
frequently requiring hospitalization, has also limited the clinical
use of amphotericin B.
Miltefosine (Impavido) is a new oral agent that has shown high
cure rates in visceral leishmaniasis in India (L. donovani; 94% cure)
[12], and in cutaneous leishmaniasis in Colombia (L. panamensis;
.90% cure) [13]. However, a recent therapeutical trial has
revealed a limited potential of miltefosine for the treatment of
American cutaneous leishmaniasis, with an unsatisfactory cure
rate of 69.8% in Colombia [14]. Furthermore, this percentage fell
to 49% when miltefosine was administered to patients with lesions
caused by L. braziliensis, which comprise more than 60% of
cutaneous leishmaniasis in Colombia [14]. Additional recent
clinical trials in Brazil showed a cure rate of miltefosine for the
treatment of cutaneous leishmaniasis caused by L. braziliensis of
75% [15], and for the treatment of cutaneous leishmaniasis caused
by L. guyanensis of 71% [16]. Miltefosine treatment also led to
approximately 70% cure rate for mucosal leishmaniasis due to L.
braziliensis in Bolivia [17,18]. Moreover, the miltefosine cure rate
was approximately 53% for cutaneous leishmaniasis (33% for L.
braziliensis infection, and 60% for L. mexicana infection) in
Guatemala [13,19,20], and a cure rate of 63% was reported for
L. tropica in Afghanistan [20]. These figures contrast with cure rates
of more than 82% in the treatment of visceral leishmaniasis (kala-
azar) in India [21,22] and Bangladesh [23]. These data point out
the great variability in the outcome depending on the geographical
area for reasons that are not well understood. In addition,
miltefosine commonly induces gastrointestinal side-effects, such as
anorexia, nausea, vomiting and diarrhea, that sometimes lead to
drop out from treatment [1,2,22]. Miltefosine is potentially
teratogenic and should not be administered to pregnant women
[1,2], for whom adequate contraception should be guaranteed
during treatment and for up to 3 months afterwards [1], given the
teratogenic potential of miltefosine in animal models [24]. An
additional concern is the rapid in vitro generation of resistance to
miltefosine [25–27] that could limit its clinical use. Thus, these
studies reinforce the need to search for new therapeutic
alternatives in the treatment of leishmaniasis.
Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phospho-
choline, ET-18-OCH3) is a promising antitumor ether lipid drug
[28–30], which is not mutagenic and acts by activating apoptosis
through its interaction with cell membranes [31–34]. In addition
to its antitumor activity, edelfosine has been shown to exert in vitro
antiparasitic activity against different species of Leishmania parasites
[35–37]. Edelfosine has been considered the prototype molecule of
a rather heterogeneous family of synthetic compounds collectively
known as alkyl-lysophospholipid analogs (ALPs), that comprise the
above clinically relevant miltefosine as well as perifosine, which
also shows anti-Leishmania activity [38,39]. Although the mecha-
nism of action of miltefosine against Leishmania parasites remains to
be fully elucidated, there are some reports showing that the ability
of this compound to promote an apoptosis-like cell death is critical
for its leishmanicidal activity [40,41]. Because edelfosine has been
shown to have a higher proapototic activity than both miltefosine
and perifosine in human cancer cells [29,30,33], we have carried
out here a comprehensive in vitro and in vivo study, investigating the
putative anti-Leishmania traits of edelfosine, as compared to other
ALPs, using different Leishmania species as well as mouse and
hamster experimental models.
Materials and Methods
Ethics statement
Animal procedures in this study complied with the Spanish
(Real Decreto RD1201/05) and the European Union (European
Directive 2010/63/EU) guidelines on animal experimentation for
the protection and humane use of laboratory animals, and were
Author Summary
Leishmaniasis represents a major international health
problem, has a high morbidity and mortality rate, and is
classified as an emerging and uncontrolled disease by the
World Health Organization. The migration of population
from endemic to nonendemic areas, and tourist activities
in endemic regions are spreading the disease to new areas.
Unfortunately, treatment of leishmaniasis is far from
satisfactory, with only a few drugs available that show
significant side-effects. Here, we show in vitro and in vivo
evidence for the antileishmanial activity of the ether
phospholipid edelfosine, being effective against a wide
number of Leishmania spp. causing cutaneous, mucocuta-
neous and visceral leishmaniasis. Our experimental mouse
and hamster models demonstrated not only a significant
antileishmanial activity of edelfosine oral administration
against different wild-type Leishmania spp., but also
against parasites resistant to pentavalent antimonials,
which constitute the first line of treatment worldwide. In
addition, edelfosine exerted a higher antileishmanial
activity and a lower proneness to generate drug resistance
than miltefosine, the first drug against leishmaniasis that
can be administered orally. These data, together with our
previous findings, showing an anti-inflammatory action
and a very low toxicity profile, suggest that edelfosine is a
promising orally administered drug for leishmaniasis, thus
warranting clinical evaluation.
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conducted at the accredited Animal Experimentation Facility
(Servicio de Experimentacio´n Animal) of the University of
Salamanca (Register number: PAE/SA/001). Procedures were
approved by the Ethics Committee of the University of Salamanca
(protocol approval number 48531).
Drugs
Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phospho-
choline) was from INKEYSA (Barcelona, Spain) and Apointech
(Salamanca, Spain). Miltefosine (hexadecylphosphocholine) was
from Calbiochem (Cambridge, MA). Perifosine (octadecyl-(1,1-
dimethyl-piperidinio-4-yl)-phosphate) and erucylphosphocholine
((13Z)-docos-13-en-1-yl 2-(trimethylammonio)ethyl phosphate)
were from Zentaris (Frankfurt, Germany). Stock sterile solutions
of the distinct ALPs (2 mM) were prepared in RPMI-1640 culture
medium (Invitrogen, Carlsbad, CA), supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin (GIBCO-BRL,
Gaithersburg, MD) as previously described [28].
Leishmania cells and culture conditions
The following Leishmania strains were used in this study: L.
amazonensis (MHOM/Br/73/LV78), L. braziliensis (MHOM/CO/
88/UA301), L. donovani (MHOM/IN/80/DD8), L. infantum
(MCAN/ES/96/BCN150), L. major LV39 (MRHO/SU/59/P),
L. mexicana (MHOM/MX/95/NAN1), and L. panamensis
(MHOM/CO/87/UA140).
Leishmania promastigotes were grown in RPMI-1640 culture
medium, supplemented with 10% FBS, 2 mM glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin at 26uC.
Promastigotes were treated with the indicated compounds during
their logarithmic growth phase (1.56106 parasites/ml) at 26uC.
Late stationary promastigotes were obtained after incubation of
the parasites for 5–6 days with starting inocula of 16106 parasites/
ml. Leishmania axenic amastigotes were obtained at pH 5.0 in
Schneider’s culture medium following a stepped temperature
increase to 30, 31 and 32uC, except for L. infantum amastigotes,
which were exposed to 34, 36 and 37uC, as previously described
[42].
Growth inhibition assay
The antileishmanial activity in promastigotes and axenic
amastigotes was determined by using the XTT (sodium 3,39-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro)
benzene sulfonic acid hydrate) cell proliferation kit (Roche
Molecular Biochemicals, Mannheim, Germany) as previously
described [42,43]. Cells were resuspended in FBS-containing
RPMI-1640 culture medium (1.56106 cells/ml for promastigotes,
and 26106 cells/ml for axenic amastigotes), and plated (100 ml/
well) in 96-well flat-bottomed microtiter plates at 26uC, in the
absence and in the presence of different concentrations of the
indicated ALPs. After 72-h incubation at 26uC, IC50 (half-
maximal inhibitory concentration) values, defined as the drug
concentration causing 50% inhibition in cell proliferation with
respect to untreated controls, were determined for each com-
pound. Measurements were done in triplicate, and each
experiment was repeated four times.
Analysis of apoptosis-like cell death by flow cytometry
One and a half million Leishmania spp. promastigotes or axenic
amastigotes were treated in the absence and in the presence of the
indicated concentrations of ALPs for different incubation times.
Then, parasites were pelleted by centrifugation (10006g) for 5 min,
and analyzed for apoptosis-like DNA breakdown by flow cytometry
following a protocol previously described [44]. Quantitation of
apoptotic-like cells was monitored as the percentage of cells in the
sub-G0/G1 region (hypodiploidy) in cell cycle analysis [44,45], using
a fluorescence-activated cell sorting (FACS) Calibur flow cytometer
(Becton Dickinson, San Jose, CA) equipped with a 488 nm argon
laser. WinMDI 2.8 software was used for data analysis.
Intracellular distribution of fluorescent edelfosine analog
in L. panamensis–infected J774 macrophages
The mouse macrophage-like cell line J774, grown in RPMI-
1640 culture medium, supplemented with 10% FBS, 2 mM L-
glutamine, 100 U/mL penicillin, and 100 mg/ml streptomycin, at
37uC in humidified 95% air and 5% CO2, was infected overnight
at the exponential growth phase (36105 cells/ml) with stationary-
phase L. panamensis promastigotes, at a macropage/promastigote
ratio of 1/10 in complete RPMI-1640 culture medium. Non-
internalized promastigotes were removed by 2–3 successive washes
with PBS. Then, uninfected and L. panamensis-infected J774
macrophages were incubated for 1 h with 10 mM of the
fluorescent edelfosine analog all-(E)-1-O-(159-phenylpentadeca-
89,109,129,149-tetraenyl)-2-O-methyl-rac-glycero-3-phosphocholine
(PTE-ET) [34,46,47] (kindly provided by F. Amat-Guerri and
A.U. Acun˜a, Consejo Superior de Investigaciones Cientı´ficas,
Madrid, Spain) in complete RPMI-1640 culture medium. In
addition, J774 cells were also incubated first with 10 mM PTE-ET
for 1 h, then washed with PBS and infected with L. panamensis in
the darkness for 6 h. Samples were fixed with 1% formaldehyde,
and analyzed with a Zeiss Axioplan 2 fluorescence microscope
(Carl Zeiss GmbH, Oberkochen, Germany) (406magnification).
Assessment of intracellular parasitic load in macrophage-
like cells
J774 cells were infected with L. panamensis promastigotes as
above. The number of intracellular viable parasites was assessed
by incubating infected cells with RPMI-1640 medium containing
0.008% SDS to gently disrupt macrophage plasma membrane,
followed by addition of RPMI-1640 culture medium containing
20% FBS to stop further lysis. Samples were then sequentially
diluted in 96-well plates containing biphasic Novy-MacNeal-
Nicolle (NNN) medium. Plates were incubated at 26uC for 20
days, and examined weekly under an inverted Nikon TS-100
microscope (Nikon, Kanagawa, Japan) to evaluate the presence of
viable motile promastigotes. The reciprocal of the highest dilution
found positive for parasite growth was considered to be the
concentration of parasites.
Determination of nitric oxide (NO) by the nitrite assay
Macrophage-like J774 cells were plated in complete RPMI-
1640 culture medium at a concentration of 16106 cells/well in 24-
well culture plates (Costar, Cambridge, MA), and let them adhere
for 2 h at 37uC in 5% CO2. Non-adhering cells were removed by
gentle washing with complete RPMI-1640 culture medium.
Adherent J774 cells were incubated in the absence (negative
control), or in the presence of 10 mg/ml lipopolysaccharide
(Sigma, St. Louis, MO) (LPS; positive control) or of different
concentrations of edelfosine. After 18-h incubation at 37uC in 5%
CO2, supernatants were collected, centrifuged at 5006 g for
10 min, and stored at 280uC until analysis. NO release was
indirectly measured using a colorimetric assay based on the Griess
reaction. Triplicate 100-ml aliquots of cell culture supernatants
were incubated with 50 ml of freshly prepared Griess reagent (1%
sulfanilamide, 0.1% naphthylethylene diamide dihydrochloride,
Antileishmanial Activity of Ether Lipid Edelfosine
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and 2.5% orthophosphoric acid) for 15 min at room temperature,
and then absorbance of the azo-chromophore was measured at
550 nm. Nitrite concentration was determined by using sodium
nitrite as a standard. All samples were assayed against a blank
comprising complete RPMI-1640 culture medium incubated for
18 h on the same plates as the samples, but in the absence of cells.
All reagents were purchased from Sigma. Results were expressed
in nanomoles of nitrite per 106 macrophages.
Evaluation of antileishmanial activity in mouse and
hamster models
Six-week-old female BALB/c mice (18–20 g) and four-week-old
male Syrian golden hamsters (Mesocricetus auratus) (about 120 g)
(Charles River Laboratories, Lyon, France), kept in a pathogen-
free facility and handled according to institutional guidelines,
complying with the Spanish legislation under a 12/12-h light/dark
cycle at a temperature of 22uC, received a standard diet and water
ad libitum. Mice were inoculated s.c. into their left hind footpad (in a
total volume of 50 ml PBS) with 26106 infective stationary-phase
promastigotes, whereas hamsters, previously anesthetized with
inhaled Forane, were inoculated intradermally in the nose with
16106 stationary-phase promastigotes in a volume of 50 ml PBS.
When inflamation was evident (about 1 week in mice, and 6 weeks
in hamsters, after inoculation), animals were randomly assigned
into cohorts of 7 animals each, receiving a daily oral administra-
tion (through a feeding needle) of edelfosine (15 mg/kg for mice,
and 26 mg/kg for hamsters, in water), or an equal volume of
vehicle (water). In mice, the footpad thickness was measured with
calipers every week, and compared with the uninfected right hind
footpad to obtain the net increase in footpad swelling. In hamsters,
nose swelling was measured with calipers every week, and
compared with the nose size before inoculation and treatment.
Evolution index of the lesion was calculated as size of the lesion
during treatment (mm)/size of the lesion before treatment. Animal
body weight and any sign of morbidity were monitored. Drug
treatment lasted for 28 days, and animals were killed following
institutional guidelines, 24 h after the last drug administration.
After the killing of the animals, the parasite burden in the infected
tissues was determined by limiting dilution assays as previously
described [48]. Biopsies were washed 3 times with PBS supple-
mented with 100 units/ml penicillin and 100 mg/ml streptomycin
(GIBCO-BRL), and then incubated overnight (12 h) at 4uC with
PBS containing 100 units/ml of penicillin and 100 mg/ml
streptomycin. Following overnight incubation, biopsies were
washed 2–3 times with PBS supplemented with the above
antibiotics, and then a weighed piece of the infected area was
homogenized in 1 ml PBS containing antibiotics using a sterile glass
Potter-Elvejhem type tissue grinder. Homogenate was diluted at a
final concentration of 0.1 mg/ml in Schneider’s culture medium,
containing 100 units/ml penicillin and 100 mg/ml streptomycin;
and then serial dilutions were made in triplicate in 96-well plates
containing biphasic Novy-MacNeal-Nicolle (NNN) medium. Plates
were incubated at 26uC for 20 days, and examined weekly under an
inverted Nikon TS-100 microscope to evaluate the presence of
viable promastigotes. The reciprocal of the highest dilution found
positive for parasite growth was considered to be the concentration
of parasites per mg of tissue. Total parasite load was calculated using
the total weight of the respective infected organ.
Induction of in vitro resistance to Glucantime in L.
panamensis promastigotes
Parasites cultured in Schneider’s culture medium supplemented
with 10% FBS, 100 units/ml penicillin, and 100 mg/ml strepto-
mycin at 26uC for 5 days, were washed twice with PBS, and
centrifuged at 10006 g for 10 min at room temperature. Parasites
were then resuspended at 26106 promastigotes/ml in Schneider’s
culture medium, and incubated at 26uC for 5 days with 4 mg/ml
Glucantime (Aventis Pharma, Sao Paulo, Brazil), which corre-
sponded to its IC50 value, previously assessed by the XTT
technique. Drug-containing culture medium was changed every 4–
6 days, depending on parasite growth, and parasites were washed
with PBS, analyzed by XTT assay, and resuspended again at
26106 parasites/ml. This procedure was repeated until parasite
viability in the presence of the drug was over 80%. Then, after
achieving this viability rate, this process was repeated three times,
with increasing concentrations of SbV, up to reaching a final
concentration of 37 mg/ml. The volume of drug solution used in
each passage was controlled not to exceed 10% of the total volume
of culture medium.
Assessment of L. panamensis resistance to SbV in the
hamster animal model
The level of SbV resistance was further assessed by infection of
golden hamsters with the above in vitro-generated SbV-resistant
(SbV-R) L. panamensis parasites, growing in the presence of 37 mg/
ml SbV, as well as with wild-type susceptible L. panamensis,
followed by treatment with Glucantime. Hamsters were divided
into two groups, eight animals infected with the resistant strain and
eight animals infected with the susceptible strain. Each group was
inoculated intradermally on the nose with 16106 stationary-phase
promastigotes in a volume of 50 ml PBS. These animals were
previously anesthetized with ketamine (50 mg/ml) and xylazine
(5 mg/kg) intraperitoneally. About six weeks after infection,
lesions were evident in both animal groups, and animals were
treated daily with 40 mg/kg Glucantime, intramuscularly using a
27-gauge needle, for ten days. Evolution of the lesions and drug
efficacy were monitored as above.
Induction of in vitro resistance to ALPs in different
Leishmania species
ALP-resistant Leishmania strains were generated as indicated
above for SbV-resistant parasites. Drugs were initially incubated at
their corresponding IC50 values, and then drug concentration was
gradually increased. Parasites were considered resistant when they
could grow at a drug concentration of 30 mM.
Statistical analysis
Data are shown as mean 6 SD. Between-group statistical
differences were assessed using the Mann-Whitney or the
Student’s t test. A P-value of ,0.05 was considered statistically
significant.
Results
ALPs differentially inhibit the proliferation of Leishmania
spp. promastigotes
We analyzed the antileishmanial potential of the four most
clinically relevant ALPs, namely edelfosine, miltefosine, perifosine
and erucylphosphocholine (Figure 1). By using the XTT assay, we
found that edelfosine and perifosine were the most active ALPs
inhibiting proliferation of distinct Leishmania spp. promastigotes
with IC50 values in the range of low micromolar concentration
(,2–9 mM) in most cases (L. donovani, L. panamensis, L. mexicana, L.
major, L. amazonensis) (Table 1). L. braziliensis and L. infantum
promastigotes were more resistant to the action of edelfosine,
perifosine and miltefosine than the other Leishmania species tested
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(Table 1). Erucylphosphocholine was the least efficient ALP in
inhibiting parasite proliferation regarding most Leishmania spp.
promastigotes, but interestingly it showed the highest antiparasitic
activity against L. infantum promastigotes (Table 1). In general, the
antileishmanial activity of the distinct ALPs ranked edelfosine$-
perifosine.miltefosine.erucylphosphocholine against Leishmania
spp. promastigotes.
Effect of ALPs in inhibiting proliferation of Leishmania
spp. axenic amastigotes
Next, we analyzed the antileishmanial activity of the distinct
ALPs against distinct axenic Leishmania amastigotes. Following an
axenic amastigote drug screening, we found that edelfosine and
perifosine behaved as the most potent ALPs in the inhibition of
proliferation of distinct Leishmania spp. amastigotes (Table 1). A
wider range of IC50 values was detected for amastigote than for
promastigote forms of Leishmania (Table 1). The IC50 values for
the anti-Leishmania amastigote activity of edelfosine and perifosine
ranged between ,3–12 mM and ,2–15 mM, respectively.
Miltefosine showed a higher degree of variability (IC50, ,4–
39 mM), with L. panamensis amastigotes being rather resistant
(IC50, 39.3 mM) (Table 1). Erucylphosphocholine showed the
highest IC50 values (,28–66 mM) for the inhibition of cell growth
in all the Leishmania spp. amastigotes analyzed (Table 1).
Surprisingly, L. infantum amastigotes were very sensitive to the
action of perifosine, edelfosine and miltefosine, whereas their
cognate promastigotes forms were rather resistant (Table 1), with
double digit IC50 figures for promastigotes and low one-digit IC50
values for amastigotes. Interestingly, L. braziliensis amastigotes
were far more sensitive to edelfosine and miltefosine than their
promastigote counterparts (Table 1), whereas perifosine and
erucylphosphocholine showed similar IC50 values for both L.
braziliensis promastigote and amastigote forms with IC50 figures
over 14 mM (Table 1). In general, the antileishmanial activity of
the distinct ALPs ranked edelfosine$perifosine.miltefosine.er-
ucylphosphocholine against Leishmania spp. amastigotes. These
results indicate that sensitivity of Leishmania parasites to ALPs is
highly dependent on each species as well as on their stage form,
namely promastigote or amastigote. Interestingly, because we
have recently found that the level of edelfosine in plasma, after
daily oral administration of 30 mg/kg, was about 10.3–25.2 mM
in both BALB/c and immunodeficient mice [29,30,49], a dose
that was effective in inhibiting cancer cell growth in vivo
[29,30,50], our results indicate that edelfosine was active against
all Leishmania spp. tested at pharmacologically relevant concen-
trations (Table 1).
Figure 1. Chemical structures of edelfosine, miltefosine, perifosine and erucylphosphocholine.
doi:10.1371/journal.pntd.0001612.g001
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Edelfosine is the most potent ALP in inducing apoptosis-
like cell death in Leishmania promastigotes
The above results showed that ALPs were able to inhibit
Leishmania spp. proliferation at distinct rates. We next analyzed
whether these agents, used at the pharmacologically relevant
concentration of 10 mM, were able to induce an apoptotic-like cell
death in Leishmania spp. promastigotes by determining DNA
fragmentation by flow cytometry. Parasites displaying a sub-G0/
G1 hypodiploid DNA content represent cells that undergo DNA
breakdown and an apoptotic-like cell death [51]. We found that
edelfosine was the most active ALP in promoting a potent
apoptotic-like response in all Leishmania spp. tested (Figure 2A). The
well nigh absence of apoptotic response in L. infantum promasti-
gotes (Figure 2A) was expected, as ALPs were used at 10 mM,
below the IC50 value for the inhibition of L. infantum promastigote
proliferation measured by XTT assays (Table 1). Interestingly,
edelfosine showed a much higher proapoptotic-like activity against
L. donovani and L. mexicana promastigotes than miltefosine and
perifosine (Figure 2A), despite the similar IC50 values (,2–3 mM)
of the three ALPs, assessed by XTT assays (Table 1). These results
suggest that the induction of cell death by edelfosine might differ
somewhat from the way by which miltefosine and perifosine
promote parasite killing. The ability of the distinct ALPs to induce
apoptosis-like cell death in Leishmania spp. promastigotes ranked
edelfosine.perifosine>miltefosine.erucylphosphocholine. Re-
sults shown in Figure 2A also show that the ability of edelfosine
to promote an apoptosis-like cell death is highly dependent on the
Leishmania sub-genus. In this regard, edelfosine inhibited prolifer-
ation of L. amazonensis (sug-genus Leishmania) and L. braziliensis (sug-
genus Viannia) promastigotes with XTT IC50 values of 6.4 and
18.3 mM, respectively (Table 1), but the percentage of parasites
with a sub-G0/G1 hypodiploid DNA content was higher in L.
braziliensis than in L. amazonensis promastigotes (Figure 2A).
L. infantum promastigotes behaved somewhat different from
other Leishmania species, with regard to their sensitivity to undergo
apoptosis-like cell death by ALPs, requiring high ALP concentra-
tions. A dose-response analysis of the apoptotic-like response of L.
infantum promastigotes to the four ALPs tested was in agreement
with the above XTT IC50 values of the corresponding drugs (cf.
Figure 2B and Table 1), with erucylphosphocholine as the most
efficient ALP at 30 mM (Figure 2B). However, at higher
concentrations, edelfosine became as efficient as erucylphospho-
choline in prompting an apoptotosis-like cell death in L. infantum
promastigotes (Figure 2B).
A comparative dose-response analysis showed that edelfosine
was more potent than miltefosine in inducing apoptosis-like cell
death in L. panamensis promastigotes (Figure 2, C and D), edelfosine
being highly effective even at 5 mM. These results agree with our
above data on XTT IC50 figures (Table 1). The cell cycle profiles
from propidium iodide-stained L. panamensis promastigotes showed
a high percentage of parasites with apoptosis-like DNA breakdown
following edelfosine treatment at either 5 or 10 mM (Figure 2, C
and D), whereas miltefosine induced only a significant DNA
breakdown response at 10 mM (Figure 2, C and D). Interestingly,
edelfosine also induced apoptosis-like cell death in L. panamensis
axenic amastigotes (25.864.6 and 55.462.8% sub-G0/G1 cells
(n = 3) after 24 h incubation with 10 and 20 mM edelfosine,
respectively).
Edelfosine accumulates in intracellular Leishmania
parasites
Because Leishmania parasites use macrophages as their main host
cell in mammalian infection, we next analyzed the localization of
edelfosine in Leishmania-infected macrophages. To this aim, we used
the fluorescent edelfosine analog all-(E)-1-O-(159-phenylpentadeca-
89,109,129,149-tetraenyl)-2-O-methyl-rac-glycero-3-phosphocholine
(PTE-ET), which has been previously used as a bona fide
compound to analyze the subcellular localization of edelfosine
in cancer cells [30,34,46,52,53], and it fully mimics the antitumor
[30,34,46,52,53] and antileishmanial [54] (data not shown)
Table 1. Inhibition of proliferation of different Leishmania spp. (IC50 values) by ALPs.
Parasite stage IC50 (mM)
Promastigotes Edelfosine Miltefosine Perifosine ErPC
L. amazonensis 6.460.3 13.060.8 9.661.8 40.063.0
L. braziliensis 18.363.7 37.763.2 14.362.1 21.063.5
L. donovani 2.160.3 3.160.8 2.260.4 13.361.2
L. infantum 27.764.6 47.364.1 35.362.5 16.762.8
L. major 2.060.2 6.860.3 7.160.5 12.761.5
L. mexicana 2.460.2 2.760.7 2.560.1 11.164.9
L. panamensis 2.360.8 6.360.6 2.460.2 14.163.1
IC50 (mM)
Axenic amastigotes Edelfosine Miltefosine Perifosine ErPC
L. amazonensis 3.160.1 5.961.2 2.960.5 42.963.9
L. braziliensis 8.160.2 6.561.2 15.163.0 28.260.7
L. donovani 5.360.2 14.560.5 9.960.7 47.763.9
L. infantum 4.260.6 4.461.1 1.760.2 37.063.1
L. mexicana 5.261.4 4.460.8 2.560.8 37.667.8
L. panamensis 12.261.2 39.363.7 9.360.8 65.866.7
Leishmania parasites were incubated with edelfosine, miltefosine, perifosine and erucylphosphocholine (ErPC), and assayed for growth inhibition by XTT assays as
described in Materials and Methods. Data are shown as the mean values 6 SD of four independent determinations.
doi:10.1371/journal.pntd.0001612.t001
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Figure 2. Differential ability of ALPs to induce apoptosis-like cell death in Leishmania spp. (A) Promastigotes from different Leishmania
spp. were treated with 10 mM edelfosine, miltefosine, perifosine or erucylphosphocholine (ErPC) at 26uC for 24 h. Apoptosis-like cell death was then
quantitated as percentage of parasites in the sub-G0/G1 region by flow cytometry. (B) L. infantum promastigotes were incubated with different
concentrations of edelfosine, miltefosine, perifosine and erucylphosphocholine (ErPC) at 26uC for 24 h, and then apoptosis-like cell death was
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actions of the parent drug edelfosine. The mouse macrophage-like
cell line J774 was rather resistant to undergo apoptosis following
treatment with edelfosine (IC50 = 40.767.1 mM, assessed by XTT
assays), and therefore it was used as a host cell line for Leishmania
infection. Edelfosine (10 mM) was unable to induce apoptosis in
J774 cells following 24 h incubation (,2% apoptosis), and caused
less than 15% apoptosis after 48 h incubation. This is in stark
contrast to the high sensitivity of other monocyte-like cell lines to
edelfosine, such as human U937 cells [28,55,56], which undergo
rapid apoptosis and can therefore not be used as host cells to
analyze the effect of ALPs on intracellular parasites residing in
macrophages. Incubation of J774 macrophages with PTE-ET
showed that the fluorescent edelfosine analog was taken up into
the cell (Figure 3A). The blue fluorescence of PTE-ET was mainly
located around the nucleus (Figure 3A, left panel) that could be
related to a predominant accumulation of this ether lipid in the
endoplasmic reticulum of J774 cells, as previously reported for
solid tumor cells [50,52]. When macrophages were infected with
L. panamensis parasites, an intense blue fluorescence was detected
in the intracellular parasites (Figure 3A, middle panel), indicating
that a major location of the PTE-ET fluorescent compound
turned out to be in the intracellular parasites inside the
macrophage. The PTE-ET location in the parasites residing in
the macrophage was clearly detected, irrespective of whether
PTE-ET was incubated with macrophages previously infected
with parasites (Figure 3A, middle panel), or with intact
macrophages and then subsequently incubated with parasites
(Figure 3A, right panel). Macrophages containing a low number
of Leishmania amastigotes are shown in Figure 3 in order to
facilitate visualization of the fluorescent drug location in the
parasites (Figure 3A). Similar data were obtained with primary
mouse bone marrow-derived macrophages, which were resistant
to 10 mM edelfosine, following infection with L. major (data not
shown). These data suggest that edelfosine accumulates in
intracellular Leishmania parasites inside macrophages, in a similar
way as PTE-ET, to exert its anti-parasite action regardless drug
treatment is before or after infection.
Edelfosine induces cell death of Leishmania amastigotes
inside macrophages
We also found that edelfosine efficiently killed J774 macrophage-
residing L. panamensis by examining the parasitic burden of
macrophages through limiting dilution assays (Figure 3B). The
cytotoxic action of edelfosine against intracellular L. panamensis
amastigotes was further confirmed by a dramatic decrease in the
number of intracellular parasites, using J774 macrophages infected
with green fluorescent L. panamensis, previously transfected with p.6.5-
egfp to express green fluorescent protein (GFP) [57] (data not shown).
Some anti-parasite drugs are suggested to promote their action
through the generation of nitric oxide (NO) [58], as this molecule
exerts an important anti-parasitic effect [59,60]. Miltefosine has
been reported to induce NO in U937 cells [61]. However, we were
unable to detect NO production following incubation of 10 mM
edelfosine with J774 macrophages (,2 nmol nitrites/106 J774
cells after 18 h incubation), unlike cell incubation with 10 mg/ml
LPS (100 nmol nitrites/106 J774 cells after 18 h incubation).
Likewise, edelfosine treatment failed to prompt NO synthesis in
mouse bone marrow-derived macrophages and rat alveolar
macrophages (data not shown). These data suggest that the killing
effect of edelfosine on macrophage-residing Leishmania parasites
does not depend on NO generation.
In vivo antileishmanial activity of edelfosine in a mouse
model
We next examined the in vivo antileishmanial activity of
edelfosine in BALB/c mice infected subcutaneously in the footpad
with 26106 infective stationary-phase L. major promastigotes. In
agreement with previous estimates [29,30,49], we found that a
daily oral administration of 15 or 30 mg/kg edelfosine was well
tolerated, 45 mg/kg being the maximum tolerated dose, following
toxicity analyses, where animals were monitored for body weight
loss or any appreciable side-effect, including changes in strength
and general condition (data not shown). We found that a daily oral
administration dose of 15 mg/kg body weight edelfosine achieved
a remarkable inhibition of both footpad inflammation (Figure 4A)
and parasitic load (Figure 4B), as assessed by caliper measures of
footpad swelling and limiting dilution assays, respectively, at the
end of the 28-day treatment period. In comparison experiments,
we found that oral treatment of L. major-infected BALB/c mice
determined by flow cytometry. (C) Representative histograms of cell cycle analysis of L. panamensis promastigotes treated with 5 and 10 mM
edelfosine and miltefosine at different incubation times. The position of the sub-G0/G1 peak, integrated by parasites undergoing apoptosis-like cell
death, is indicated by arrows. Percentages of apoptotic parasites are shown in each histogram. (D) L. panamensis promastigotes were treated with 5
and 10 mM edelfosine or miltefosine at different incubation times, and then apoptosis-like cell death was determined by flow cytometry. Untreated
Leishmania promastigotes were run in parallel, and apoptosis-like cell death was less than 1.5% in untreated parasites in all cases shown in panels A–
D. Data are means 6 SD or representative of four independent experiments. Asterisks indicate that the differences between edelfosine- and
miltefosine-treated cells are statistically significant. (*) P,0.05. (**) P,0.01.
doi:10.1371/journal.pntd.0001612.g002
Figure 3. Antileishmanial activity of edelfosine against intra-
cellular Leishmania amastigotes within macrophage-like J774
cells. (A) J774 cells, incubated with the blue-emitting fluorescent
analog PTE-ET (left panel), or with L. panamensis (Lp) and then with PTE-
ET (middle panel), or with PTE-ET and then with L. panamensis (Lp) (right
panel), were analyzed by fluorescence microscopy to examine drug
localization. White arrows point to the intracellular amastigotes. (B)
Parasite burden in L. panamensis-infected J774 cells untreated (Control)
and treated with 5 or 10 mM edelfosine for 24 h. Data are means 6 SD
or representative of four independent experiments. Asterisks indicate
that the differences between control and edelfosine-treated groups are
statistically significant. (*) P,0.05. (**) P,0.01.
doi:10.1371/journal.pntd.0001612.g003
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with edelfosine was slightly more effective than with miltefosine,
although differences were not statistically significant (data not
shown). The dose of edelfosine used in our assays was similar to the
dose used for miltefosine in mouse models, ranging from 2.5 to
25 mg/kg of body weight/day given orally, and being 20 mg/kg/
day the most widely used dose for in vivo murine experiments
[35,39,62–65]. In addition, because the molecular masses for
edelfosine and miltefosine are 523.7 and 407.6, respectively, the
edelfosine dose used in our assays (15 mg/kg, corresponding to
28.6 mmol/kg) was even lower than the usual miltefosine dose
(20 mg/kg, corresponding to 49.1 mmol/kg) in these in vivo murine
studies.
In vivo antileishmanial activity of edelfosine in hamster
models of cutaneous and mucocutaneous leishmaniasis
Next, we used golden hamsters as an additional experimental
animal model of leishmaniasis. Hamsters have been reported to
better reproduce the clinicopathological features of human
leishmaniasis than mice [66–68]. One million promastigotes of
L. panamensis and L. braziliensis were inoculated in the nose of
golden hamsters, as animal models for cutaneous and mucocu-
taneous leishmaniasis, since the above Leishmania species can
cause both cutaneous and mucocutaneous disease [69,70]. Then,
hamsters were randomized into drug-treated and drug-free
control (water vehicle) groups of seven hamsters each, and the
animal models for L. panamensis (Figure 5, A–C) and L. braziliensis
(Figure 5, D–F) infections were monitored for the antileishma-
nial efficacy of edelfosine. Serial caliper measurements during
the course of the assays were made to determine the rate of nose
swelling (Figure 5, A and D). Progression of the disease led to a
dramatic swelling and ulceration of the nose. Oral administra-
tion of edelfosine (26 mg/kg body weight) on a daily basis for 4
weeks (28 days) induced a remarkable decrease in both nasal
swelling and parasitic load at the site of infection (Figure 5). This
dose is lower than the miltefosine dose (40 mg/kg/day) used in a
recent study with L. donovani-infected hamsters [71]. Here, we
found no appreciable adverse effects on the general condition of
the animals following a daily oral administration of 26 mg/kg
edelfosine. The effect of edelfosine on nose swelling became
evident in both L. panamensis and L. braziliensis infections after
two weeks of treatment (Figure 5, A and D). The parasite loads,
assessed by limiting dilution assays, were significantly diminished
in both animal models following oral treatment with edelfosine
(Figure 5, B and E). Untreated infected animals displayed
intense swelling and ulceration in their noses, but edelfosine
treatment greatly ameliorated the signs of leishmaniasis (Figure 5,
E and F).
Edelfosine shows potent in vitro and in vivo
antileishmanial activity against SbV-resistant L.
panamensis parasites
Cutaneous leishmaniasis is the most common form of
leishmaniasis and is endemic in many tropical and subtropical
countries [1,2]. Common therapies for leishmaniasis for more
than 60 years include the use of SbV drugs as meglumine
antimoniate (Glucantime) or sodium stibogluconate (Pentostam)
[2,72]. However, extensive use of these compounds is leading to
SbV resistance. Thus, parasites have become resistant to
antimony in many parts of the world, and primary resistance to
SbV exceeds 60% of cases of leishmaniasis in the state of Bihar in
India [73]. Different Leishmania species have been shown to
display distinct susceptibility to antimonials [74,75]. In addition,
susceptibility of L. donovani to SbV has been reported to follow
stage transformation from promastigotes to axenic amastigotes,
while resistance to SbV is acquired when amastigotes differentiate
into promastigotes [76]. SbV has also been reported to be active,
even though to different degrees, against a number of Leishmania
spp. promastigotes and amastigotes in vitro, including L. panamensis
[77–81]. On these grounds and because of possible clinical
implications, we generated a SbV-resistant L. panamensis strain to
be tested for the antiparasitic activity of the distinct ALPs.
Induction of resistance to SbV in L. panamensis promastigotes was
achieved by continuous in vitro exposure of these parasites to
increasing Glucantime concentrations for 1 year. The SbV-
resistant L. panamensis strain was able to resist concentrations of
Glucantime as high as 36 mg/ml, as assessed by XTT assays, a
concentration 9-fold higher than the IC50 (4 mg/ml) for wild type
L. panamensis promastigotes. Because of the different susceptibility
to SbV shown by certain Leishmania spp., depending on their
promastigote or amastigote stage, SbV resistance of L. panamensis
promastigotes was further evaluated by in vivo experiments in a
hamster model. Two groups of eight hamsters each were
inoculated in the nose with wild type and SbV-resistant L.
panamensis promastigotes, and then, after a 6-week post-infection
period, when nose swelling was clearly detected, hamsters were
injected intramuscularly with 40 mg/kg body weight Glucantime
(SbV), on a daily basis for 4 weeks. As shown in Figure 6 (A and
B), swelling was decreased in animals infected with wild type L.
panamensis, but increased in animals infected with SbV-resistant L.
panamensis. In addition, macrophages infected with Leishmania
amastigotes were readily observed in smears from the nose of
SbV-resistant L. panamensis-infected hamsters, but not from wild
type L. panamensis-infected animals, treated with SbV (Figure 6B).
Moreover, the parasitic burden in the nose of the two groups of
animals indicated that the amount of viable wild type L.
panamensis was dramatically diminished following treatment with
the pentavalent antimonial drug, but the SbV-resistant L.
panamensis parasites remained viable in the in vivo assay (data
not shown). These results indicate that the generated SbV-
resistant L. panamensis strain was highly resistant to pentavalent
antimonial treatment both in vitro and in vivo.
Next, we tested in vitro the activity of the four ALPs edelfosine,
miltefosine, perifosine and erucylphosphocholine against both wild
type and SbV-resistant L. panamensis promastigotes by XTT assays.
We found that all ALPs were effective in inhibiting proliferation of
SbV-resistant L. panamensis promastigotes showing similar IC50
values to those found against wild type L. panamensis (Figure 6C).
Figure 4. In vivo antileishmanial action of edelfosine in L. major-
infected mice. BALB/c mice were infected with 26106 L. major
promastigotes in the left hind footpad, and after swelling was
perceptible, mice were randomized into drug-treated (15 mg edelfo-
sine/kg of body weight, daily oral administration for 28 days) and
control (water vehicle) groups of 7 mice each. After completion of the
4-week treatment, lesions were evaluated by measuring the footpad
swelling (A) and determining the parasite load (B), using caliper
measurements and limiting dilution assays respectively. Data are means
6 SD (n= 7). Asterisks indicate that the differences between control and
edelfosine-treated groups are statistically significant. (**) P,0.01.
doi:10.1371/journal.pntd.0001612.g004
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Edelfosine was the most effective ALP against SbV-resistant L.
panamensis promastigotes and no difference in edelfosine sensitivity
was observed between wild type and SbV-resistant strains
(Figure 6C).
Infection of hamsters with SbV-resistant L. panamensis parasites
in the nose, showed that a daily oral treatment with edelfosine
(26 mg/kg body weight) for 4 weeks led to a dramatic decrease in
the evolution index, parasitic burden and local inflammation
(Figure 6, D–F). The first signs of improvement were detected after
about two weeks of treatment (Figure 6A). These data indicate that
oral treatment with edelfosine was efficient against leishmaniasis
caused by SbV-resistant L. panamensis parasites.
Differential time requirement for the generation of
resistance to edelfosine and miltefosine in Leishmania
spp. promastigotes
A major concern in anti-parasitic chemotherapy is the
generation of drug resistance. Thus, we next analyzed the
feasibility to generate drug resistance to miltefosine and edelfosine
in different Leishmania species, by a gradual increase in drug
concentration. We determined the time required to achieve
resistance to 30 mM miltefosine or edelfosine. This drug
concentration could be appropriate to distinguish between specific
and unspecific effects, and thereby drug resistance was considered
Figure 5. In vivo antileishmanial action of edelfosine in L. panamensis- and L. braziliensis-infected hamsters. Golden hamsters were
infected with 16106 L. panamensis or L. braziliensis promastigotes in the nose, and after swelling was perceptible, hamsters were randomized into
drug-treated (26 mg edelfosine/kg of body weight, daily oral administration for 28 days) and control (water vehicle) groups of 7 hamsters each. (A, D)
Lesion development was monitored by measuring nose thickness at regular intervals, and comparison to values obtained before treatment
(evolution index). (B, E) Parasite load was determined by limiting dilution assays after completion of the 4-week in vivo assays. Data are means 6 SD
(n=7). Asterisks indicate that the differences between control and edelfosine-treated groups are statistically significant. (*) P,0.05. (**) P,0.01. (C, F)
Edelfosine treatment led to a dramatic decrease and amelioration in parasite-induced nose thickness and damage, as shown by representative
photographs from drug-free control and edelfosine-treated hamsters.
doi:10.1371/journal.pntd.0001612.g005
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Figure 6. Sensitivity of SbV-resistant L. panamensis parasites to edelfosine. (A) Two groups of eight golden hamsters each were infected in
the nose with wild type and SbV-resistant L. panamensis (Lp) promastigotes, and after the sixth week post-infection, they were treated with a daily
intramuscular injection of Glucantime (SbV) for 4 weeks. Disease evolution rate was measured along the whole process through determining nose
thickness as compared to figures obtained before infection. (B) Golden hamsters inoculated with SbV-resistant (SbV-R) L. panamensis (Lp) did not
respond to treatment with Glucantime (inflamed nose) (upper left panel), and nose smears showed amastigotes within macrophages (arrow)
following Giemsa staining (lower left panel). However, hamsters infected with wild type (wt) L. panamensis (Lp) fully responded to Glucantime
treatment, showing uninflamed nose and negative staining for amastigotes in nose smears (upper and lower right panels). (C) IC50 values of
edelfosine, miltefosine, perifosine, and erucylphosphocholine (ErPC) for in vitro growth inhibition of wild type (wt) and SbV-resistant (SbV-R) L.
panamensis (Lp) promastigotes were determined by XTT assays. (D–F) Golden hamsters were infected with 16106 SbV-resistant L. panamensis
promastigotes in the nose, and after nose inflammation was evident, hamsters were randomized into drug-treated (26 mg edelfosine/kg of body
weight, daily oral administration for 28 days) and control (water vehicle) groups of 7 hamsters each. (D) Lesion development was monitored by
measuring nose thickness at regular intervals and comparison to values obtained before treatment (evolution index). (E) Parasite load was
determined by limiting dilution assays after completion of the 4-week in vivo assay. (F) Edelfosine treatment led to a dramatic decrease and
amelioration in parasite-induced nose thickness and damage, as shown by photographs from drug-free control and edelfosine-treated hamsters.
Data are means 6 SD or representative experiments (n= 7). Asterisks indicate that differences between control and edelfosine-treated groups, or
between wild type and SbV-resistant parasites treated with SbV, are statistically significant. (*) P,0.05. (**) P,0.01.
doi:10.1371/journal.pntd.0001612.g006
Antileishmanial Activity of Ether Lipid Edelfosine
www.plosntds.org 11 April 2012 | Volume 6 | Issue 4 | e1612
when parasites became resistant to a final drug concentration of
30 mM. We found that the continuous exposure of L. donovani, L.
major and L. panamensis promastigotes to increasing amounts of
miltefosine led to a rather rapid advent of drug resistance following
40–64 days of treatment (Table 2). However, relatively more
protracted continuous treatments were required to generate
edelfosine resistance in L. major and L. panamensis promastigotes
(Table 2). Interestingly, whereas miltefosine treatment led to drug
resistance in L. donovani after a relatively short period of time
(Table 2), no drug resistance was detected after 100-day treatment
of L. donovani with edelfosine (Table 2).
Discussion
Our results show the in vitro and in vivo antileishmanial activity of
edelfosine against different Leishmania species. The ability of
edelfosine to kill distinct Leishmania spp. promastigotes and
amastigotes is in general higher than other ALPs, and the
antileishmanial activity of ALPs ranked edelfosine.perifosine.-
miltefosine.erucylphosphocholine. Edelfosine also shows a higher
capacity to induce an apoptosis-like cell death in Leishmania than
miltefosine (Impavido), which has been approved as the first oral
drug active against visceral leishmaniasis [2]. However, recent
studies have challenged the efficacy of miltefosine against some
cutaneous leishmaniasis [13–15,17–20], and relapse cases of
miltefosine-treated parasites have been reported in visceral and
diffuse cutaneous leishmaniasis [82–84] as well as in HIV-positive
patients [85,86].
Here, we have found that edelfosine shows an outstanding
activity against a wide number of Leishmania spp. causing
cutaneous, mucocutaneous and visceral leishmaniasis. Edelfosine
was able to kill parasites in both promastigote and amastigote
forms through an apoptosis-like process that involved DNA
degradation, as assessed by an increase in the percentage of cells
with a hypodiploid DNA content. Leishmania parasites infect
macrophages wherein they reside and replicate in a fusion
competent vacuole (parasitophorous vacuole). Interestingly,
edelfosine efficiently killed intracellular parasite amastigotes
inside macrophages, without affecting the host cells. This killing
activity on intracellular parasites seems to be mainly due to a
direct action of the drug on the parasite, as edelfosine was unable
to induce NO generation in macrophages, while a fluorescent
edelfosine analog accumulated in the intracellular parasites
within macrophages.
Our data also reveal a remarkable antileishmanial activity of
edelfosine in several in vivo assays using mouse and hamster animal
models infected with L. major, L. panamensis or L. braziliensis. To our
knowledge this is the first study using hamsters as animal models
for the in vivo evaluation of ALPs against cutaneous leishmaniasis.
In addition, both in vitro and in vivo evidence showed that edelfosine
was very effective against SbV-resistant Leishmania parasites. This is
of importance as pentavalent antimonials Glucantime and
Pentostam are being used in the treatment of leishmaniasis for
over more than six decades, and still they are the first line drugs of
choice and the traditional treatment worldwide. However,
resistance to pentavalent antimonials is emerging as a result of
their widespread use. A stark example of SbV resistance is well
documented in Bihar (India), which houses approximately 90% of
Indias’s cases of visceral leishmaniasis, representing about 50% of
the world’s cases, and where resistance ended the usefulness of
SbV more than a decade ago [2].
A major potential drawback in the use of miltefosine could be
the relatively rapid generation of drug resistance in vitro. We have
found here that generation of drug resistance required longer
incubation times of Leishmania spp. with edelfosine than with
miltefosine. Furthermore, whereas miltefosine generated drug
resistance in L. donovani following a 40-day treatment, no resistance
to edelfosine was detected after 100-day incubation.
It is worthwhile to note that miltefosine treatment has been
reported to be unsatisfactory against infections caused by L.
braziliensis [13–15,17–20], whereas here we have found a
remarkable antiparasitic activity of edelfosine in L. braziliensis-
infected hamsters. In addition, edelfosine offers a number of
additional advantages as compared to miltefosine, such as the
fact that edelfosine shows a potent anti-inflammatory action
[87], and no apparent toxicity [87]. Leishmania parasites enter
first neutrophils through the regulation of granule fusion
processes that prevents any deleterious action on the parasite
[88]. Leishmania parasites use polymorphonuclear neutrophils as
intermediate hosts before their ultimate delivery to macrophages,
following engulfment of parasite-infected neutrophils, and in this
way Leishmania can escape the host immune system [89]. A
significant part of the destruction caused by cutaneous
leishmaniasis is due to severe inflammation at the site of
infection in the skin, leading to ulceration [90]. Neutrophils are
recruited into the site of infection during cutaneous leishmaniasis
[91,92], and accumulation of neutrophils have been linked to
tissue damage [93]. Edelfosine induces L-selectin (CD62L)
shedding, and thus prevents neutrophil extravasation to the
inflammation or infection site [87]. On these grounds, leish-
maniasis could be ameliorated by oral treatment of edelfosine,
which could reduce the parasite burden, by direct parasite
killing, as well as the ulcerative process and subsequent scar
formation, by a reduction in the recruitment of neutrophils into
the site of infection.
A serious drawback of miltefosine is its teratogenic effects [24],
however no studies have been conducted so far for a putative
teratogenic action of edelfosine.
The studies reported here provide compelling evidence for the
potent antileishmanial activity of edelfosine, which together with
the low toxicity profile displayed by this ether lipid and its anti-
inflammatory activity, warrants further clinical evaluation as a
possible alternative treatment against leishmaniasis.
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